

May 18, 2017

**The Manager Listing**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Scrip code: 532531

**The Manger Listing**

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

**Sub: Outcome of Board Meeting – Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2017**

The Board of Directors at their meeting held today i.e., on May 18, 2017, have approved and adopted the Audited Financial Statements along with the Auditors' Report for the financial year ended March 31, 2017.

Please find enclosed herewith the following:

- 1) Audited Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2017; and
- 2) Press Release.


Further, the Board of Directors of the Company have recommended dividend of 45% at Rs. 4.50/- per share for the year ended March 31, 2017. The dividend payout shall be made within 30 days from the date of shareholder approval at the ensuing Annual General Meeting of the Company.

The board meeting commenced at 1330 hrs and concluded at 1500 hrs.

This is for your information and record.

Thanks & Regards,

**For Strides Shasun Limited**

  
**Manjula Ramamurthy**  
**Company Secretary**



## Press Release

**Strides Shasun announces Q4 FY17 results**  
**Q4 FY17 Pharma Revenues at INR 9,231 Mn, EBITDA at INR 2,162 Mn**  
**FY 17 Pharma Revenues at INR 35,106 Mn up 23%, EBITDA at INR 7,230 Mn up 33%**  
**Achieves 95% of H2 FY 17 guidance despite delays in product approvals**  
**Board Recommends Dividend of INR 4.50 per share (45%)**

**Bengaluru, May 18, 2017:** Strides Shasun Limited (BSE: 532531, NSE: STAR) today announced its Q4 FY17 and FY 17 results

### Performance versus guidance for H2 FY 17

- The Company guided for an EBITDA of INR 4,400 – 4,750 Mn for H2 FY 17.
- Guidance was based on 5-6 new product approvals for the North America market. These approvals have been delayed and are now expected in H2 FY 18. Majority of the filings were from the Puducherry facility which recently completed USFDA inspection with Zero 483 observations
- Sevelamer carbonate API sales were lower than planned due to delay in approvals of Gx Renvela for partners.
- Institutional sales during Q4 FY 17 tracked lower on account of timing of new tender awards
- The Company has achieved 95% of the guidance with H2 FY 17 EBITDA at INR 4,200 Mn despite a challenging operating environment.


### Consolidated Financial & Performance Highlights (Pharma & Biotech) INR Mn

| Particulars | Q4 FY16* | Q4 FY 17*    | YoY     | FY 16  | FY 17*        | YoY     |
|-------------|----------|--------------|---------|--------|---------------|---------|
| Revenues    | 9,163    | <b>9,231</b> | 1%      | 28,499 | <b>35,106</b> | 23%     |
| EBITDA      | 1,857    | <b>2,133</b> | 15%     | 5,220  | <b>7,191</b>  | 38%     |
| EBITDA %    | 20%      | <b>23%</b>   | 280 bps | 18%    | <b>20%</b>    | 220 bps |

\*The CRAMS business was sold during Q2 FY 17. Q4 FY 16, FY 16 and FY 17 numbers does not include contribution from CRAM's

- The results have been prepared as per Indian Accounting Standards (Ind-AS).
- Total revenues for Q4 FY 17 at INR 9,231 Mn against INR 9,163 Mn in Q4 FY16, up 1% YoY.
- Total revenues for FY 17 at INR 35,106 Mn against INR 28,499 Mn in FY16, up 23 % YoY.
- EBITDA for Q4 FY 17 at INR 2,133 Mn up 15 % YoY, EBITDA margins at 23 % up 280 bps YoY.
- EBITDA for FY 17 at INR 7,191 Mn up 38 % YoY, EBITDA margins at 20 % up 220 bps YoY.

**Shashank Sinha, Group CEO**, stated "We delivered a solid quarter. Key products continue to gain market share driving growth in the base business. New product filing momentum picked up as we nearly doubled R&D investments. Our last four consecutive USFDA audits have been successful with zero 483's. A strong pipeline, compliant manufacturing base and growing market presence are the pillars of our future growth"



## Pharma Performance Highlights – Q4 FY 17 and FY 17

### Global Pharma Business

**INR Mn**

| Particulars     | Q4 FY 16 | Q4 FY 17     | YoY     | FY 16  | FY 17         | YoY     |
|-----------------|----------|--------------|---------|--------|---------------|---------|
| Revenues        | 9,163    | <b>9,231</b> | 1%      | 28,499 | <b>35,106</b> | 23%     |
| EBITDA          | 1,905    | <b>2,162</b> | 14%     | 5,417  | <b>7,230</b>  | 33%     |
| EBITDA %        | 21%      | <b>23%</b>   | 260 bps | 19%    | <b>21%</b>    | 160 bps |
| Adj Pharma EPS* |          |              |         |        | 50.76*        |         |

\*Excluding Merger & restructuring costs of INR 234 Mn, Fair valuation of derivative Instruments INR 182 Mn and Biotech INR 125 Mn


### Revenue Composition by Business - Global Pharma

**INR**
**Mn**

| Particulars               | Q4 FY 16     | Q4 FY 17     | YoY   | FY 16  | FY 17         | YoY   |
|---------------------------|--------------|--------------|-------|--------|---------------|-------|
| Regulated Markets         | 3,857        | <b>5,267</b> | 37%   | 11,395 | <b>17,762</b> | 56%   |
| Emerging Markets          | 1,038        | <b>1,420</b> | 37%   | 3,839  | <b>6,330</b>  | 65%   |
| Institutional Business    | 2,072        | <b>1,026</b> | (50%) | 5,951  | <b>5,677</b>  | (5%)  |
| <b>Total Formulations</b> | <b>6,967</b> | <b>7,714</b> | 11%   | 21,185 | <b>29,769</b> | 40%   |
| API                       | 2,196        | <b>1,517</b> | (31%) | 7,314  | <b>5,336</b>  | (27%) |
| <b>Total Revenues</b>     | <b>9,163</b> | <b>9,231</b> | 1%    | 28,499 | <b>35,106</b> | 23%   |

### Regulated Markets Business

- Revenues at INR 5,267 Mn in Q4 FY 17, up 37 % YoY.
- Revenues up 56% YoY in FY 17 to INR 17,762 Mn, representing 51% of total revenues.
- In North America, grew market share with marginal price erosion. While the front end delivered a steady quarterly performance, the partnered portfolio witnessed certain pricing challenges. Frontend performance was driven by sequential improvement in market share for key products including Dutasteride, Ergocalciferol, Methoxsalen. Ranitidine, the first integrated product approval from Strides Shasun stable that was commercialised during the last quarter has now successfully garnered 18% market share, up from 6% last quarter.
- During FY 17 Company received 6 new product approvals - tentative approval for Efavirenz Tablet, two FTF approval for Roflumilast tablets and Fingolimod Capsules, approvals for Metronidazole Tablet, Ranitidine tablet and Polyethylene Glycol 3350, Powder for Solution (OTC).
- The Company has visibility of 15-20 product approvals for North America market over the next 12 months across various dosage formats.
- Australia business delivered a healthy quarter with commercialisation of 6 new products. Arrow has launched a total of 20 new products in FY 17 and will continue to expand its product portfolio including new products from Generic Partners. Pharmacy Alliance has scaled up its coverage to over 600 + pharmacies to become the largest buying group in Australia. With an expanding pharmacy coverage, focus is now on better compliance for Arrow products at store level. Backward integration of the product portfolio to start yielding material savings in FY 18.



**Emerging Markets Business**

- Revenues at INR 1,420 Mn in Q4 FY 17, up 37% YoY.
- Revenues up 65% YoY in FY 17 to INR 6,330 Mn, representing 18% of total revenues.
- Sequential decline in emerging markets revenues largely on account of ramp down of the generics manufacturing business in Africa ahead of planned exit.
- The branded generics business and Universal corporation business in Africa delivered a steady quarterly performance despite impact from depreciation in key billing currencies of EUR and USD. Added ~ 50 medical representatives in Africa for the branded business during FY 17. Focus on adding new products, expanding distribution network and improving field force productivity in Africa.
- India brands business reported a tepid performance due to a carry forward impact of demonetization in the early half of the quarter. Currently witnessing a trend towards lower stocking level in the channel ahead of the GST roll out. Focus on leveraging a pan India distribution network across the product portfolio and improving field force productivity.

**Institutional Business**


- Revenues at INR 1,026 Mn in Q4 FY17, versus INR 2,072 Mn in Q4 FY 16.
- Revenues decline 5% YoY in FY 17 to INR 5,677 Mn, representing 16% of total revenues.
- Decline in institutional business attributed to significantly lower contribution from Anti- Malarial portfolio during the quarter. While the Company has been able to maintain its market share, the overall funding to the donor programs has seen a decline. The ARV business continues to witness healthy traction.
- Initiated tech transfer of existing institutional products to WHO approved facility of Universal Corporation in Kenya, supplies to start in H2 FY 18.
- R&D focus on developing next generation products in line with evolving treatment regimens.

**Active Pharmaceutical Ingredients (API)**

- Revenues at INR 1,517 Mn in Q4 FY 17, versus INR 2,196 in Q4 FY 16.
- Revenues decline 27% YoY in FY 17 to INR 5,336 Mn, representing 15% of total revenues.
- Portfolio rationalisation and increased captive consumption for the formulations helped deliver superior margins for the API business during the year.
- Scaled up filings for high entry barrier markets like Japan and Korea.

**Pharma R&D**

- The R&D set up gained momentum with 9 filings in FY 17.
- Significant scale up in R&D investments during FY 17 to build the future product pipeline.
- R&D spend for the quarter at INR 322 Mn against INR 172 Mn in Q4 FY 16, up 87 % YoY.
- R&D spend for FY 17 at INR 1,361 Mn against INR 757 Mn in FY 16, up 80 % YoY.
- Formulations and API R&D teams working on a joint development platform to build a portfolio of integrated products.



- The Company made 8 filings in H2 FY 17 against a guidance of 10-12 filings.
- Expect the filing momentum to continue in FY 18 with a target of 15-20 product filings spread across multiple dosage formats.
- 32 ANDA filings pending approval from USFDA.

### **Manufacturing Infrastructure**

Four manufacturing facilities, the formulation facilities in Bangalore and Puducherry, the API facilities at Cuddalore and Puducherry, were inspected by the US FDA over the last twelve months and all the facilities were cleared without any observations.

- Continue to invest in people, practices and technology for superior compliance.
- The Company has an upcoming USFDA audit in May 2017 at its flagship plant in Bangalore. The plant has a host of key products pending approval from USFDA.
- Singapore formulation facility for regulated markets is expected to go on stream in H2 FY 18.
- Signed definitive agreements with Vivimed Labs Limited to enter into 50:50 Joint Ventures for its US FDA formulations facility at Alathur, Chennai. The Joint venture will provide access to additional capacities to the tune of 1.5 billion tablets/ capsules per annum and a strong product pipeline. This JV will also help de-risking of manufacturing base.

### **Corporate Updates**

#### **Board Level Changes**

The Company has completed several organic and inorganic strategies to put in place pivots for growth. To guide the management team in rolling out the future strategies, which are predominately directed towards B2C businesses, the Board is being re-constituted.

- Arun Kumar, Founder and Executive Vice Chairman will move to a Non-Executive position as Chairman of the Board. He will continue to provide strategic inputs to the management. .
- Homi Rustam Khusrokhani will join the Board as an Independent Director. Over the last five decades, he has held senior positions in GSK, Tata Group, ICICI Bank among others.
- Shashank Sinha, Group CEO and Badree Komandur, Group CFO will join the board as Executive Directors.
- After long and distinguished association with the Company, M.R. Umarji, P.M. Thampi, A.K. Nair and Abhaya Kumar will relinquish their board position

### **Other Corporate Updates**

#### **Acquisition of Perrigo's US FDA approved API facility in India**

- In December 2016, Company announced definitive agreements to acquire the entire shareholding in Perrigo API India Private Limited (Perrigo API India) for INR 1000 Million.
- The transaction has achieved closure.
- The facility will be used for captive consumption and will supply strategic API for the formulations business. The Company will transfer all the key integrated DMFs for captive consumption to the acquired facility.

#### **Exiting the Africa generics manufacturing Business**



- In February 2017, Company had announced its exit from the Africa generics manufacturing business including 6 generic facilities in Africa for a cash consideration of US\$ 16 Mn.
- The transaction has achieved closure.

**De-merger of the API business to Solara Active Pharma Sciences**

- In February 2017, Company had announced the de-merger of its commodity API business to Solara Active Pharma Sciences (previously SSL Pharma Sciences Limited).
- During Q4 FY 17 the board of directors on the recommendation of the audit committee approved the composite scheme of arrangement to be entered between Strides Shasun Limited, SeQuent Scientific Limited and Solara Active Pharma Sciences for the de-merger.
- The board of directors have also approved the share entitlement ratio of 1 equity share of Rs 10 each of Solara Active Pharma Sciences for every 6 equity shares held in Strides Shasun Limited.
- The Scheme is subject to statutory approvals including from the shareholders and creditors of the Company, Sequent and SSL, Stock Exchanges where the shares of Strides and SeQuent are listed, the Securities and Exchange Board of India, National Company Law Tribunal and the Competition Commission of India.
- The appointed date for the Scheme of Merger will be October 1, 2017.

**Strides' investment in Stelis Biopharma Private Limited**

- In February 2017, Company had announced capping Strides' equity investment in Stelis at US\$ 22 Mn for a significant minority stake.
- Post receiving the shareholders' approval and meeting customary closing conditions, the transaction has now achieved closure.



## Annexure:

### EBITDA Computation: In INR Mn

|                                                                      | Q4 FY 17     | FY 17        |
|----------------------------------------------------------------------|--------------|--------------|
| <b>SEBI Results</b>                                                  |              |              |
| Profit/(loss) before exceptional items and tax as per SEBI reporting | <b>1,179</b> | <b>3,973</b> |
| Less: Interest, Dividend income, Gain on sale of securities          | <b>(133)</b> | <b>(863)</b> |
| <i>Add : Depreciation and Amortization</i>                           | <b>529</b>   | <b>1,872</b> |
| Add : Finance Cost                                                   | <b>592</b>   | <b>2,269</b> |
| EBITDA from continuing operations                                    | <b>2,166</b> | <b>7,251</b> |
| Add: EBITDA from Discontinued Operations (Excluding CRAMS)           | <b>(4)</b>   | <b>(21)</b>  |
| EBITDA as per press release                                          | <b>2,162</b> | <b>7,230</b> |

### About Strides Shasun

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients (API).

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com)


### For further information, please contact:

|                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b><u>Strides</u></b><br><br>Badree Komandur, Executive Director<br>+91 80 6784 0747<br><br><b><u>Investors:</u></b><br><br>Kannan. N: +91 98450 54745<br>Vikesh Kumar: +91 80 6784 0827<br>Sandeep Baid : +91 80 6784 0791 | <b><u>PR Consultancy</u></b><br><br><b>Fortuna PR</b><br>K Srinivas Reddy: +91 9000527213<br><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a><br><br>K Priya: +91 9535425418<br><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|




**STATEMENT OF CONSOLIDATED AUDITED RESULTS**  
**FOR THE YEAR ENDED MARCH 31, 2017**

| Sl. No. | Particulars                                                                       | 3 Months ended 31.03.2017 (Refer note 17) |     | Preceding 3 months ended 31.12.2016 |     | Corresponding 3 Months ended 31.03.2016 in the previous year |     | Current year ended 31.03.2017 |     | Rs. in Lakhs<br>Previous year ended 31.03.2016 |     |
|---------|-----------------------------------------------------------------------------------|-------------------------------------------|-----|-------------------------------------|-----|--------------------------------------------------------------|-----|-------------------------------|-----|------------------------------------------------|-----|
|         |                                                                                   | UNAUDITED                                 | (1) | UNAUDITED                           | (2) | UNAUDITED                                                    | (3) | AUDITED                       | (4) | AUDITED                                        | (5) |
| I       | <b>Continuing Operations</b>                                                      |                                           |     |                                     |     |                                                              |     |                               |     |                                                |     |
| II      | Revenue from operations                                                           | 88,841                                    |     | 93,353                              |     | 92,432                                                       |     | 348,342                       |     | 286,219                                        |     |
| III     | Other Income                                                                      | 7,305                                     |     | 2,018                               |     | 2,784                                                        |     | 16,858                        |     | 9,210                                          |     |
|         | <b>Total Revenue (I + II)</b>                                                     | <b>96,146</b>                             |     | <b>95,371</b>                       |     | <b>95,216</b>                                                |     | <b>365,200</b>                |     | <b>295,429</b>                                 |     |
| IV      | <b>Expenses</b>                                                                   |                                           |     |                                     |     |                                                              |     |                               |     |                                                |     |
|         | (a) Cost of material consumed                                                     | 25,869                                    |     | 26,546                              |     | 44,752                                                       |     | 103,114                       |     | 134,033                                        |     |
|         | (b) Purchases of stock-in-trade                                                   | 13,468                                    |     | 20,030                              |     | 11,888                                                       |     | 65,900                        |     | 27,205                                         |     |
|         | (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | (902)                                     |     | (6,079)                             |     | (8,173)                                                      |     | (15,394)                      |     | (11,009)                                       |     |
|         | (d) Employee benefits expense                                                     | 15,241                                    |     | 15,193                              |     | 10,470                                                       |     | 58,812                        |     | 35,770                                         |     |
|         | (e) Finance costs                                                                 | 5,919                                     |     | 5,383                               |     | 6,170                                                        |     | 22,693                        |     | 16,817                                         |     |
|         | (f) Depreciation and amortisation expense                                         | 5,289                                     |     | 4,753                               |     | 3,934                                                        |     | 18,715                        |     | 13,125                                         |     |
|         | (g) Other expenses                                                                | 19,473                                    |     | 17,693                              |     | 22,922                                                       |     | 71,628                        |     | 58,823                                         |     |
|         | <b>Total Expenses (IV)</b>                                                        | <b>84,357</b>                             |     | <b>83,519</b>                       |     | <b>91,963</b>                                                |     | <b>325,468</b>                |     | <b>274,764</b>                                 |     |
| V       | <b>Profit/(loss) before exceptional items and tax (III - IV)</b>                  | <b>11,789</b>                             |     | <b>11,852</b>                       |     | <b>3,253</b>                                                 |     | <b>39,732</b>                 |     | <b>20,665</b>                                  |     |
| VI      | <b>Exceptional Items:</b>                                                         |                                           |     |                                     |     |                                                              |     |                               |     |                                                |     |
|         | - Exchange Fluctuation (loss) / gain (Net) (Refer note 14)                        | 2,897                                     |     | (1,212)                             |     | 2,704                                                        |     | 1,105                         |     | 555                                            |     |
|         | - Impairment of Goodwill                                                          | (794)                                     |     | -                                   |     | -                                                            |     | (794)                         |     | -                                              |     |
|         | - Write-off/provision for impairment of assets (net)                              | -                                         |     | (6,032)                             |     | (6,301)                                                      |     | (6,301)                       |     | (653)                                          |     |
|         | - Interest Income                                                                 | -                                         |     | 124                                 |     | -                                                            |     | 124                           |     | -                                              |     |
|         | - Reversal of provision for impairment of fixed assets                            | -                                         |     | -                                   |     | 40                                                           |     | -                             |     | 40                                             |     |
|         | - Merger and restructuring costs                                                  | (699)                                     |     | (648)                               |     | (874)                                                        |     | (2,343)                       |     | (2,212)                                        |     |
|         | - Recovery / (write off) of loans & advances given in earlier years (net)         | (516)                                     |     | -                                   |     | 4                                                            |     | (29)                          |     | 135                                            |     |
|         | - Fair valuation of derivative instruments                                        | (1,058)                                   |     | (286)                               |     | (1,50)                                                       |     | (1,820)                       |     | (320)                                          |     |
|         | - Impact of aligning accounting policies on merger of Shasun (Refer note 2)       | -                                         |     | -                                   |     | -                                                            |     | -                             |     | (1,682)                                        |     |
|         | <b>Total Exceptional Items (VI)</b>                                               | <b>(170)</b>                              |     | <b>(8,054)</b>                      |     | <b>1,071</b>                                                 |     | <b>(10,058)</b>               |     | <b>(4,137)</b>                                 |     |
| VII     | <b>Profit/(loss) before tax (V + VI)</b>                                          | <b>11,619</b>                             |     | <b>3,798</b>                        |     | <b>4,324</b>                                                 |     | <b>29,674</b>                 |     | <b>16,528</b>                                  |     |
| VIII    | Share of profit / (loss) of joint ventures and associates                         | 69                                        |     | (13)                                |     | (15)                                                         |     | 36                            |     | (468)                                          |     |
| IX      | <b>Profit/(loss) before tax (VII + VIII)</b>                                      | <b>11,688</b>                             |     | <b>3,785</b>                        |     | <b>4,309</b>                                                 |     | <b>29,710</b>                 |     | <b>16,060</b>                                  |     |
| X       | <b>Tax expense</b>                                                                |                                           |     |                                     |     |                                                              |     |                               |     |                                                |     |
|         | - Current tax                                                                     | 538                                       |     | 3,745                               |     | 256                                                          |     | 6,590                         |     | 2,806                                          |     |
|         | - Deferred tax                                                                    | 1,208                                     |     | (2,963)                             |     | 1,702                                                        |     | (1,891)                       |     | 1,440                                          |     |
|         | <b>Total tax expense (X)</b>                                                      | <b>1,746</b>                              |     | <b>782</b>                          |     | <b>1,958</b>                                                 |     | <b>4,699</b>                  |     | <b>4,246</b>                                   |     |
| XI      | <b>Profit/(loss) after tax from continuing operations (IX - X)</b>                | <b>9,942</b>                              |     | <b>3,003</b>                        |     | <b>2,351</b>                                                 |     | <b>25,011</b>                 |     | <b>11,814</b>                                  |     |
| XII     | <b>Discontinued Operations</b>                                                    |                                           |     |                                     |     |                                                              |     |                               |     |                                                |     |
|         | - Profit/(loss) from discontinued operations before tax (Refer note 4)            | 3,364                                     |     | 16,642                              |     | (1,676)                                                      |     | 20,004                        |     | (1,416)                                        |     |
|         | - Tax expense of discontinued operations                                          | 116                                       |     | 28                                  |     | 232                                                          |     | 419                           |     | 899                                            |     |
| XIII    | <b>Profit/(loss) after tax from discontinued operations</b>                       | <b>3,248</b>                              |     | <b>16,614</b>                       |     | <b>(1,908)</b>                                               |     | <b>19,585</b>                 |     | <b>(2,315)</b>                                 |     |
| XIV     | <b>Profit/(loss) for the period (XI + XIII)</b>                                   | <b>13,190</b>                             |     | <b>19,617</b>                       |     | <b>443</b>                                                   |     | <b>44,596</b>                 |     | <b>9,499</b>                                   |     |









Regd. Office: No. 201 Devavratra, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.  
STATEMENT OF CONSOLIDATED AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

| Sl. No.    | Particulars                                                                       | Rs. in Lakhs                              |                                     |                                                              |                               |                                |
|------------|-----------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|--------------------------------|
|            |                                                                                   | 3 Months ended 31.03.2017 (Refer note 17) | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 | Previous year ended 31.03.2016 |
|            |                                                                                   | UNAUDITED (1)                             | UNAUDITED (2)                       | UNAUDITED (3)                                                | AUDITED (4)                   | AUDITED (5)                    |
| <b>XV</b>  | <b>Other comprehensive income</b>                                                 |                                           |                                     |                                                              |                               |                                |
| <b>A</b>   | (i) Items that will not be recycled to profit or loss                             | (134)                                     | (1,524)                             | (3,006)                                                      | (2,593)                       | (3,006)                        |
|            | (ii) Income tax relating to items that will not be reclassified to profit or loss | (43)                                      | -                                   | 15                                                           | 498                           | 15                             |
| <b>B</b>   | (i) Items that may be recycled to profit or loss                                  | 6,318                                     | (5,580)                             | 6,215                                                        | (1,641)                       | 5,071                          |
|            | (ii) Income tax relating to items that may be reclassified to profit or loss      | (801)                                     | 262                                 | (292)                                                        | (693)                         | (172)                          |
|            | <b>Total other comprehensive income for the period (XV)</b>                       | <b>5,340</b>                              | <b>(6,842)</b>                      | <b>2,932</b>                                                 | <b>(4,429)</b>                | <b>1,908</b>                   |
| <b>XVI</b> | <b>Total other comprehensive income for the period (XIV + XV)</b>                 | <b>18,530</b>                             | <b>12,775</b>                       | <b>3,375</b>                                                 | <b>40,167</b>                 | <b>11,407</b>                  |
|            | <b>Profit for the period attributable to:</b>                                     |                                           |                                     |                                                              |                               |                                |
|            | - Owners of the Company                                                           | 11,232                                    | 18,732                              | 1,558                                                        | 39,976                        | 10,852                         |
|            | - Non-controlling interests                                                       | 1,950                                     | 885                                 | (1,115)                                                      | 4,612                         | (1,353)                        |
|            |                                                                                   | <b>13,190</b>                             | <b>19,617</b>                       | <b>443</b>                                                   | <b>44,596</b>                 | <b>9,499</b>                   |
|            | <b>Other comprehensive income for the period</b>                                  |                                           |                                     |                                                              |                               |                                |
|            | - Owners of the Company                                                           | 5,348                                     | (6,842)                             | 2,932                                                        | (4,421)                       | 1,908                          |
|            | - Non-controlling interests                                                       | (8)                                       | -                                   | -                                                            | (8)                           | -                              |
|            |                                                                                   | <b>5,340</b>                              | <b>(6,842)</b>                      | <b>2,932</b>                                                 | <b>(4,429)</b>                | <b>1,908</b>                   |
|            | <b>Total comprehensive income for the period</b>                                  |                                           |                                     |                                                              |                               |                                |
|            | - Owners of the Company                                                           | 16,580                                    | 11,890                              | 4,490                                                        | 35,555                        | 12,760                         |
|            | - Non-controlling interests                                                       | 1,950                                     | 885                                 | (1,115)                                                      | 4,612                         | (1,353)                        |
|            |                                                                                   | <b>18,530</b>                             | <b>12,775</b>                       | <b>3,375</b>                                                 | <b>40,167</b>                 | <b>11,407</b>                  |
|            | <b>Earnings per equity share (for continuing operations):</b>                     |                                           |                                     |                                                              |                               |                                |
|            | (1) Basic (in Rs.)                                                                | 8.93                                      | 2.37                                | 3.88                                                         | 22.82                         | 15.94                          |
|            | (2) Diluted (in Rs.)                                                              | 8.92                                      | 2.37                                | 3.87                                                         | 22.77                         | 15.85                          |
|            | <b>Earnings per equity share (for discontinued operations):</b>                   |                                           |                                     |                                                              |                               |                                |
|            | (1) Basic (in Rs.)                                                                | 3.63                                      | 18.59                               | (2.13)                                                       | 21.91                         | (2.80)                         |
|            | (2) Diluted (in Rs.)                                                              | 3.63                                      | 18.56                               | (2.13)                                                       | 21.87                         | (2.79)                         |
|            | <b>Earnings per equity share (for discontinued and continuing operations):</b>    |                                           |                                     |                                                              |                               |                                |
|            | (1) Basic (in Rs.)                                                                | 12.57                                     | 20.96                               | 1.74                                                         | 44.73                         | 13.14                          |
|            | (2) Diluted (in Rs.)                                                              | 12.54                                     | 20.93                               | 1.74                                                         | 44.64                         | 13.06                          |
|            | See accompanying notes to the Financial Results                                   |                                           |                                     |                                                              |                               |                                |






Regd. Office: No. 201 Devavata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

STATEMENT OF ASSETS AND LIABILITIES

AS AT MARCH 31, 2017

| Particulars                                         | Rs in Lakhs      |                  |                  |
|-----------------------------------------------------|------------------|------------------|------------------|
|                                                     | As at 31.03.2017 | As at 31.03.2016 | As at 01.04.2015 |
|                                                     | AUDITED          | AUDITED          | AUDITED          |
| <b>A ASSETS</b>                                     |                  |                  |                  |
| <b>I Non-current assets</b>                         |                  |                  |                  |
| (a) Property, plant and equipment                   | 108,633          | 94,066           | 35,812           |
| (b) Capital work-in-progress                        | 20,450           | 29,419           | 11,232           |
| (c) Investment property                             | 7,060            | 7,469            | 7,831            |
| (d) Goodwill                                        | 96,696           | 92,672           | 13,684           |
| (e) Other intangible assets                         | 86,021           | 79,584           | 12,894           |
| (f) Intangibles assets under development            | 57,532           | 53,614           | 2,546            |
| (g) Financial assets                                |                  |                  |                  |
| (i) Investments                                     | 24,507           | 5,250            | 6,876            |
| (ii) Loans                                          | 3,659            | 1,910            | -                |
| (iii) Other financial assets                        | 2,246            | 2,425            | 851              |
| (h) Deferred tax assets (Net)                       | 1,998            | 3,467            | 539              |
| (i) Other non-current assets                        | 21,049           | 24,236           | 10,973           |
| <b>Total non-current assets</b>                     | <b>429,851</b>   | <b>394,112</b>   | <b>103,238</b>   |
| <b>II Current assets</b>                            |                  |                  |                  |
| (a) Inventories                                     | 73,799           | 61,314           | 20,768           |
| (b) Financial assets                                |                  |                  |                  |
| (i) Investments                                     | 127,954          | 121,375          | 59,952           |
| (ii) Trade receivables                              | 99,705           | 103,297          | 36,712           |
| (iii) Cash and cash equivalents                     | 32,233           | 30,457           | 13,912           |
| (iv) Bank balances other than (iii) above           | 715              | 702              | 827              |
| (v) Loans                                           | 860              | 1,281            | 2,714            |
| (vi) Other financial assets                         | 4,265            | 1,804            | 1,022            |
| (c) Current tax assets (Net)                        | 1,701            | 828              | 379              |
| (d) Other current assets                            | 39,637           | 30,591           | 8,188            |
| <b>Total current assets</b>                         | <b>380,869</b>   | <b>351,649</b>   | <b>144,474</b>   |
| <b>Total Assets</b>                                 | <b>810,720</b>   | <b>745,761</b>   | <b>247,712</b>   |
| <b>B EQUITY AND LIABILITIES</b>                     |                  |                  |                  |
| <b>I Equity</b>                                     |                  |                  |                  |
| (a) Equity Share capital                            | 8,942            | 8,935            | 5,962            |
| (b) Other equity                                    | 262,101          | 256,851          | 109,617          |
| <b>Equity attributable to owners of the company</b> | <b>271,043</b>   | <b>265,786</b>   | <b>115,579</b>   |
| Non-Controlling interests                           | 16,399           | 5,021            | 1,392            |
| <b>Total equity</b>                                 | <b>287,442</b>   | <b>270,807</b>   | <b>116,971</b>   |
| <b>II Liabilities</b>                               |                  |                  |                  |
| <b>1 Non-current liabilities</b>                    |                  |                  |                  |
| (a) Financial liabilities                           |                  |                  |                  |
| (i) Borrowings                                      | 175,467          | 264,705          | 25,299           |
| (ii) Other financial liabilities                    | 43,016           | 15,462           | 2,080            |
| (b) Provisions                                      | 2,468            | 1,445            | 602              |
| (c) Deferred tax liabilities (Net)                  | 7,563            | 4,728            | 1,115            |
| (d) Other non-current liabilities                   | 3,069            | 1,420            | 1,422            |
| <b>Total non-current liabilities</b>                | <b>231,583</b>   | <b>287,760</b>   | <b>30,518</b>    |
| <b>2 Current liabilities</b>                        |                  |                  |                  |
| (a) Financial liabilities                           |                  |                  |                  |
| (i) Borrowings                                      | 129,984          | 70,048           | 20,303           |
| (ii) Trade payables                                 | 74,653           | 77,539           | 23,459           |
| (iii) Other financial liabilities                   | 70,779           | 28,614           | 48,539           |
| (b) Other current liabilities                       | 7,438            | 4,174            | 1,707            |
| (c) Provisions                                      | 1,834            | 1,493            | 1,297            |
| (d) Current tax liabilities                         | 7,007            | 5,326            | 4,918            |
| <b>Total current liabilities</b>                    | <b>291,695</b>   | <b>187,194</b>   | <b>100,223</b>   |
| <b>Total Equity and Liabilities</b>                 | <b>810,720</b>   | <b>745,761</b>   | <b>247,712</b>   |





**Strides Shasun**

Regd. Office: No. 201 Devavriata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017**

**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 18 May 2017.
- 2 During the previous year, pursuant to the court approved Scheme of Amalgamation (the 'Scheme'), the erstwhile Shasun Pharmaceuticals Limited (Shasun) has been amalgamated with the Company w.e.f. the appointed date of April 01, 2015.

Ind AS 103 'Business Combination' is not applicable to the above referred merger in view of the Scheme sanctioned by the Hon'ble High Courts of Judicature under section 391 to 394 of the Companies Act, 1956.

The Company has followed the 'Pooling of Interest method' as per the court approved Scheme of Amalgamation for the accounting of Assets and Liabilities of the erstwhile Shasun. The impact of aligning the accounting policies of the erstwhile Shasun with that of the Company on the assets and liabilities taken over on merger amounting to Rs. 1,682 lakhs has been expensed off in the results for the year ended 31 March 2016 under exceptional items.

The Company issued 21,017,329 equity shares of Rs. 10/- each to the shareholders of erstwhile Shasun in terms of the Scheme of Amalgamation. These shares have been considered for the purpose of calculation of earnings per share.

**3 Transition to India Accounting Standards (Ind AS)**


The Group's consolidated financial statements for the year ended 31 March 2017 are prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. The adoption of Ind AS was carried out in accordance with Ind AS 101, using 01 April 2015 as the transition date. Ind AS 101 requires that all the Ind AS standards and interpretations that are effective for the Ind AS financial statements for the year ended 31 March 2017 be applied consistently and retrospectively for all fiscal years presented. All applicable Ind AS, read with note 2 above, have been applied consistently and retrospectively wherever required. The resulting difference in the carrying amounts of assets and liabilities in the financial statements under both Ind AS and Indian GAAP as at the transition date have been recognised directly in equity at the transition date.

The following reconciliations provide a quantification of the effect of significant differences arising from the transition from India GAAP to Ind AS in accordance with Ind AS 101 for:

- (a) Equity as at 01 April 2015
- (b) Equity as at 31 March 2016
- (c) Total comprehensive income for the year ended 31 March 2016

**Equity reconciliation**

|                                                                                                                                                                         | Rs. In Lakhs   |                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|
|                                                                                                                                                                         | March 31, 2016 | April 01, 2015 |
| <b>Equity under previous GAAP as reported</b>                                                                                                                           | <b>277,384</b> | <b>108,531</b> |
| <b>IND AS adjustments:</b>                                                                                                                                              |                |                |
| Reversal of propose dividend and dividend tax                                                                                                                           | 4,322          | 1,788          |
| Relating to Goodwill                                                                                                                                                    | 2,860          | -              |
| Measurement of ESOPs at fair value                                                                                                                                      | -              | -              |
| Fair valuation of gross obligation on put options given to NCI                                                                                                          | (15,033)       | (1,315)        |
| Fair value changes in Investments through OCI                                                                                                                           | (2,867)        | -              |
| Actuarial gains/ losses through OCI                                                                                                                                     | 14             | -              |
| Impact of measuring financial instruments at fair value through profit or loss                                                                                          | (708)          | 2,500          |
| Impact of measuring ESOP at fair value                                                                                                                                  | -              | -              |
| Write off of acquisition related costs pertaining to business combinations                                                                                              | (4,395)        | -              |
| Impairment under Expected Credit Losses                                                                                                                                 | (6,356)        | (2,283)        |
| Share of loss of investment in associates and joint ventures                                                                                                            | (1,421)        | -              |
| Share of profit allocated to NCI                                                                                                                                        | 87             | -              |
| Impact of classification of subsidiary to Joint venture                                                                                                                 | 382            | -              |
| Reversal of amortisation of intangible assets on account of change in estimated useful life and impact of purchase price allocation on account of business combinations | 530            | -              |
| Other IND AS adjustments                                                                                                                                                | (386)          | 188            |
| Tax impact on above adjustments                                                                                                                                         | 2,539          | 208            |
| <b>Equity as per IND AS</b>                                                                                                                                             | <b>256,852</b> | <b>109,617</b> |



**Total comprehensive income reconciliation**

| Particulars                                                                                                                                                             | QTD March 31, 2016           |                            | YTD March 31, 2016           |                            | Rs. In Lakhs  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------|------------------------------|----------------------------|---------------|
|                                                                                                                                                                         | Statement of Profit and loss | Other comprehensive income | Statement of Profit and loss | Other comprehensive income |               |
| <b>Profit under previous GAAP as reported (after share of non-controlling interest)</b>                                                                                 | <b>9,624</b>                 | <b>-</b>                   | <b>9,624</b>                 | <b>-</b>                   | <b>20,894</b> |
| <b>IND AS adjustments:</b>                                                                                                                                              |                              |                            |                              |                            |               |
| Measurement of financial instruments at fair value through profit or loss                                                                                               | 164                          | -                          | 164                          | -                          | (3,208)       |
| Measurement of EOPs at fair value                                                                                                                                       | (90)                         | -                          | (90)                         | -                          | (331)         |
| Impairment under Expected Credit Losses                                                                                                                                 | (3,578)                      | -                          | (3,578)                      | -                          | (4,073)       |
| Reversal of amortisation of intangible assets on account of change in estimated useful life and impact of purchase price allocation on account of business combinations | 242                          | -                          | 242                          | -                          | 530           |
| Fair valuation of gross obligation on put options given to NCI                                                                                                          | (150)                        | -                          | (150)                        | -                          | (320)         |
| Write off of acquisition related costs pertaining to business combinations                                                                                              | (4,395)                      | -                          | (4,395)                      | -                          | (4,395)       |
| Other IND AS adjustments                                                                                                                                                | (53)                         | -                          | (53)                         | -                          | 87            |
| Share of loss of investment in associates and joint ventures                                                                                                            | (131)                        | -                          | (131)                        | -                          | (468)         |
| Share of profit allocated to NCI                                                                                                                                        | (84)                         | -                          | (84)                         | -                          | 87            |
| Fair valuation of equity instruments through OCI                                                                                                                        | -                            | (2,967)                    | (2,967)                      | (2,967)                    | (2,967)       |
| Movement in foreign exchange translation reserve                                                                                                                        | -                            | 5,367                      | 5,367                        | 4,572                      | 4,572         |
| Actual gains/ losses through OCI (net of taxes)                                                                                                                         | 39                           | (39)                       | -                            | (39)                       | -             |
| Unrealised gain/ (loss) on cash flow hedges through OCI (net of taxes)                                                                                                  | -                            | 848                        | 848                          | 499                        | 499           |
| Tax impact on above adjustments                                                                                                                                         | (30)                         | (277)                      | (307)                        | (157)                      | 1,853         |
| <b>Profit as per IND AS (after share of non-controlling interest)</b>                                                                                                   | <b>1,558</b>                 | <b>2,932</b>               | <b>4,490</b>                 | <b>1,908</b>               | <b>12,760</b> |


**4 Sale of investments:** During the year, the Group sold the following investments:

(a) The Board of Directors of the Company and the Members of Company in their meeting held on May 16, 2016 and June 28, 2016, subject to the approval of applicable laws, consents, permission and sanctions as may be necessary, approved the divestment of investment in Shasun Pharma Solutions Limited (SPSL), UK, a wholly owned step-down subsidiary of the Company. SPSL was in the business of Contract Research and Manufacturing. The resulting gain on disposal of these investments amounting to Rs. 1,116 Lakhs and the results of the business of Contract Research and Manufacturing are included in the details of the discontinued operations for the respective periods as set out in Note 4(d) below.

(b) During the current quarter, the Company sold its investments in Strides Biologix Private Limited, India, an erstwhile subsidiary and the related business. The resulting gain on such disposal amounting to Rs. 387 Lakhs and the results of this business are included in the details of the discontinued operations for the respective periods as set out in Note 4(d) below.

(c) Pursuant to the terms of Shareholders agreement entered on March 30, 2017, the Group disposed-off its Pharma Generics Manufacturing business in Africa. Consequently, the following subsidiaries / divisions ceased to be part of Strides Group:

- (i) African Pharmaceutical Development Company
- (ii) Congo Pharma SPRL
- (iii) Sorepharm SA
- (iv) Strides Pharma Botswana (Pty) Limited
- (v) Strides Pharma Cameroon Limited
- (vi) Strides Pharma Mozambique, SA
- (vii) Strides Pharma Namibia Pty Limited
- (viii) Strides Vital Nigeria Limited
- (ix) SPC Co. Limited, Sudan
- (x) Pharma Generics Manufacturing division of the Company in Palghar, Maharashtra.





**Strides Shasun**

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017**

The loss on disposal of the Pharma Generics Manufacturing business amounting to Rs. 9,761 Lakhs and the results of this business for the period are included in the details of the discontinued operations for the respective periods as set out in Note 4(d) below.

| Sl. No.                     | Particulars                                             | Rs. in Lakhs                              |                                     |                                                              |                               |
|-----------------------------|---------------------------------------------------------|-------------------------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|
|                             |                                                         | 3 Months ended 31.03.2017 (Refer note 17) | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 |
|                             |                                                         | UNAUDITED                                 | UNAUDITED                           | UNAUDITED                                                    | AUDITED                       |
| (d) Discontinued operations |                                                         |                                           |                                     |                                                              |                               |
| I                           | Total Revenue                                           | 3,553                                     | 2,387                               | 12,838                                                       | 26,148                        |
| II                          | Total Expenses                                          | 3,694                                     | 2,479                               | 13,360                                                       | 27,991                        |
| III                         | Profit/(loss) before exceptional items and tax (I - II) | (141)                                     | (92)                                | (522)                                                        | (1,843)                       |
| IV                          | Exceptional items                                       | (3,395)                                   | 3,601                               | 919                                                          | 6                             |
| V                           | Profit/(loss) before tax (III + IV)                     | 3,254                                     | (3,693)                             | (1,441)                                                      | (1,849)                       |
| VI                          | Tax expense                                             | (722)                                     | 28                                  | 232                                                          | (419)                         |
| VII                         | Profit/(loss) after tax (V-VI)                          | 3,976                                     | (3,721)                             | (1,673)                                                      | (1,430)                       |
| VIII                        | Gain / (loss) on disposals (net)                        | (728)                                     | 20,335                              | (235)                                                        | 21,015                        |
| IX                          | Profit/(loss) from discontinued operations              | 3,248                                     | 16,614                              | (1,908)                                                      | 19,585                        |
|                             |                                                         |                                           |                                     |                                                              | AUDITED                       |
|                             |                                                         |                                           |                                     |                                                              | 48,172                        |
|                             |                                                         |                                           |                                     |                                                              | 49,696                        |
|                             |                                                         |                                           |                                     |                                                              | (1,524)                       |
|                             |                                                         |                                           |                                     |                                                              | 919                           |
|                             |                                                         |                                           |                                     |                                                              | (2,443)                       |
|                             |                                                         |                                           |                                     |                                                              | 629                           |
|                             |                                                         |                                           |                                     |                                                              | (3,072)                       |
|                             |                                                         |                                           |                                     |                                                              | 757                           |
|                             |                                                         |                                           |                                     |                                                              | (2,315)                       |

5 Pursuant to the approvals of the board of directors of the Company and that of the shareholders, with regard to the Company's intent of capping its investments in Stelis Biopharma Private Limited ("Stelis", a company which is into development of Biosimilars) and its intention of reducing its stake to a significant minority, the Company entered into an amended shareholders agreement under which it has ceded control over Stelis but continues to exercise significant influence. In accordance with the provisions of Ind AS 110 "Consolidated Financial Statements", the resulting gain of Rs.1,078 Lakhs, being the excess of fair value of consideration over the carrying value of net assets in Stelis on loss of control over Stelis, has been accounted under discontinued operations and is included in the details provided in Note 4(d) above.

6 As part of ongoing restructuring in the group, the following changes have been made during the quarter ended 31 March 2017, within the Strides group:

(a) Strides Specialities (Holdings) Limited, Mauritius, transferred from Strides Pharma Global Pte Limited, Singapore, to Strides Pharma Asia Pte Limited, Singapore.

(b) Stelis Biopharma (Malaysia) SDN BHD, Malaysia, transferred from Stelis Biopharma Private Limited, India to Strides Pharma Asia Pte Limited, Singapore.

(c) Strides Pharma Solutions Inc., USA, transferred from SVADS Holdings SA, Switzerland to Strides Arcolab International Limited, UK.

7 In the current quarter, pursuant to the Group acquiring remaining stake in Fagris Medica Private Limited, India and Arrow Pharma Pte Limited, Singapore, these entities became wholly owned subsidiaries of the Group.


8 During the quarter ended 31 March 2017, Solara Active Pharma Sciences Limited (formerly known as SSL Pharma Sciences Limited) and Strides Consumer Private Limited, India, were incorporated as wholly owned subsidiaries of the Group.

9 In the current quarter:

(a) Pharmacy Alliance Pty Limited, Australia, a subsidiary of the Company acquired Smartpharm Pty Limited, Australia.

(b) Strides Shasun Latina Sa de CV, a joint venture between Strides Pharma Global Pte Limited, Singapore a subsidiary of the Company and Mike Padavakis, Mexico was set up.

(c) Oraderm Pharmaceuticals Pty Limited, a joint venture arrangement between Arrow Pharmaceutical Pty Limited, Australia, and Douglas Pharmaceuticals, Australia Pty Limited was set up.



10 On December 4, 2013, the Company and its wholly owned subsidiary, Strides Pharma Asia Pte Limited ("the Singapore Subsidiary"), completed the sale of investments in Agila Specialties Private Limited and Agila Specialties Global Pte Limited (together, "Agila") to Mylan Laboratories Limited and Mylan Institutional Inc. (together, "Mylan") pursuant to separate agreements, each dated as of February 27, 2013 (the "SPAs"). Pursuant to the SPAs, the Strides Group established escrow arrangements to fund certain potential indemnification liabilities, including specified employee, tax and regulatory remediation costs from such consideration. These escrow arrangements included a US\$ 100 million "General Claims Escrow" deposit (out of which US\$ 8.00 million has been settled in an earlier year to be paid to Mylan in relation to certain claims) and a US\$ 100 million "Regulatory Escrow" deposit. Pursuant to the SPAs, the Company has also provided a corporate guarantee to Mylan for US\$ 200 million (valid up to December 4, 2020) on behalf of Singapore Subsidiary which can be used for discharging financial obligations, if any, of the Singapore Subsidiary to Mylan.

Under the terms of the SPAs, claims against the Company / the Singapore subsidiary (as the case may be) can only be made under specific provisions contained in the SPAs which include the procedures and timelines for submission of notifications of claims and actual claims and commencing arbitration proceedings. The Company had received a consolidated notification of claims from Mylan under the terms of the SPAs.

These claims were related to third party claims, tax claims, claims against the regulatory escrows and general claims. In the current year, a significant portion of these claims have been settled and the Strides Group has received approximately USD 28 Million as full and final settlement from out of the Regulatory Escrow deposit. Further, the Company and Mylan also agreed on full and final settlement of warranty and indemnity claims to be adjusted against the "General Claims Escrow".

Considering the terms of the SPAs, the nature of the pending claims that are in arbitration currently and the balance available in the General Claims Escrow deposit, the Company believes that any further outflow of resources is not probable.

11 The Company has entered into definitive agreement with Perrigo Group for acquisition of Perrigo API India Private Limited. As at 31 March 2017, pending completion of certain conditions precedent and other customary closing condition, this acquisition has not been completed. On April 06, 2017, the Company has completed the acquisition of Perrigo API India Private Limited.


12 Income from Operations includes revenues from sale of products, product development services, royalties, export entitlements etc. Cost of material consumed is net of rebates, discounts, supplier reimbursements etc.

13 During the year ended 31 March 2017, 70,000 equity shares and 7,028 equity shares were allotted by the Company under the Strides Arcolab ESOP 2011 Scheme and Strides Arcolab ESOP 2015 Scheme, respectively, on exercising equal number of options.

14 Exchange fluctuation gain/loss (net) included under Exceptional Items comprises the exchange gain / loss arising on account of restatement and settlement of long term foreign currency loans and intra-group loans.



| Particulars                                                                                                   | 3 Months ended 31.03.2017 (Refer note 17) | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 | Previous year ended 31.03.2016 |
|---------------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|--------------------------------|
|                                                                                                               | UNAUDITED                                 | UNAUDITED                           | UNAUDITED                                                    | AUDITED                       | AUDITED                        |
| <b>1 Segment Revenue</b>                                                                                      |                                           |                                     |                                                              |                               |                                |
| a) Pharmaceutical business                                                                                    | 91,187                                    | 93,393                              | 101,851                                                      | 367,484                       | 321,415                        |
| b) Biotech business                                                                                           | -                                         | -                                   | -                                                            | -                             | -                              |
| <b>Revenue from operations</b>                                                                                | <b>91,187</b>                             | <b>93,393</b>                       | <b>101,851</b>                                               | <b>367,484</b>                | <b>321,415</b>                 |
| <b>2 Segment results Profit/(Loss) allocable</b>                                                              |                                           |                                     |                                                              |                               |                                |
| a) Pharmaceutical business                                                                                    | 21,043                                    | 17,088                              | 9,518                                                        | 60,272                        | 36,437                         |
| b) Biotech business                                                                                           | 388                                       | (1,442)                             | (1,647)                                                      | (1,370)                       | (3,311)                        |
| <b>Total</b>                                                                                                  | <b>21,431</b>                             | <b>15,646</b>                       | <b>7,871</b>                                                 | <b>58,902</b>                 | <b>33,126</b>                  |
| <b>Add / (Less): Unallocable Income/(expenses):</b>                                                           |                                           |                                     |                                                              |                               |                                |
| Other Income                                                                                                  | 1,333                                     | 1,813                               | (15)                                                         | 8,154                         | 2,673                          |
| Finance cost                                                                                                  | (5,599)                                   | (5,698)                             | (6,522)                                                      | (23,511)                      | (18,054)                       |
| Items considered under exceptional items:                                                                     | -                                         | -                                   | -                                                            | -                             | -                              |
| - Exchange (loss) / gain on long-term foreign currency loans, intra-group loans                               | (425)                                     | (1,697)                             | 2,704                                                        | (2,501)                       | 555                            |
| - Merger and restructuring costs                                                                              | (699)                                     | (648)                               | (874)                                                        | (2,343)                       | (2,212)                        |
| - Net gain / (loss) on discontinued businesses                                                                | -                                         | 11,310                              | (235)                                                        | 12,449                        | 1,027                          |
| - Recovery / (write off) of loans & advances given in earlier years                                           | -                                         | -                                   | (131)                                                        | 348                           | -                              |
| - Impact of aligning accounting policies on merger of Shasun (Refer note 2)                                   | -                                         | -                                   | -                                                            | -                             | (1,682)                        |
| - Fair valuation of derivative instruments                                                                    | (1,058)                                   | (286)                               | (150)                                                        | (1,820)                       | (320)                          |
| <b>Profit before tax from continuing and discontinued operations</b>                                          | <b>14,983</b>                             | <b>20,440</b>                       | <b>2,648</b>                                                 | <b>49,678</b>                 | <b>15,113</b>                  |
| Tax expense                                                                                                   | 1,862                                     | 810                                 | 2,190                                                        | 5,118                         | 5,145                          |
| <b>Profit before allocation to minority interest</b>                                                          | <b>13,121</b>                             | <b>19,630</b>                       | <b>458</b>                                                   | <b>44,560</b>                 | <b>9,968</b>                   |
| Share of profit / (loss) from associates and joint ventures                                                   | 69                                        | (13)                                | (14)                                                         | 36                            | (468)                          |
| <b>Net Profit after taxes and share of loss of associates and joint ventures but before minority interest</b> | <b>13,190</b>                             | <b>19,617</b>                       | <b>443</b>                                                   | <b>44,596</b>                 | <b>9,499</b>                   |
| Share of profit / (loss) attributable to Minority interest (net)                                              | 1,958                                     | 885                                 | (1,115)                                                      | 4,620                         | (1,353)                        |
| <b>Profit for the period</b>                                                                                  | <b>11,232</b>                             | <b>18,732</b>                       | <b>1,558</b>                                                 | <b>39,976</b>                 | <b>10,852</b>                  |
| <b>Rs. in Lakhs</b>                                                                                           |                                           |                                     |                                                              |                               |                                |
| <b>Particulars</b>                                                                                            | <b>As at 31.03.2017</b>                   |                                     | <b>As at 31.03.2016</b>                                      |                               |                                |
| <b>3 Segment Assets</b>                                                                                       |                                           |                                     |                                                              |                               |                                |
| a) Pharmaceutical business                                                                                    | 650,785                                   |                                     | 609,174                                                      |                               |                                |
| b) Biotech business                                                                                           | 20,494                                    |                                     | 19,205                                                       |                               |                                |
| c) Unallocable                                                                                                | 139,439                                   |                                     | 117,382                                                      |                               |                                |
| <b>Total Segment Assets</b>                                                                                   | <b>810,718</b>                            |                                     | <b>745,761</b>                                               |                               |                                |
| <b>4 Segment Liabilities</b>                                                                                  |                                           |                                     |                                                              |                               |                                |
| a) Pharmaceutical business                                                                                    | 137,344                                   |                                     | 104,177                                                      |                               |                                |
| b) Biotech business                                                                                           | -                                         |                                     | 1,031                                                        |                               |                                |
| c) Unallocable                                                                                                | 385,932                                   |                                     | 369,746                                                      |                               |                                |
| <b>Total Segment Liabilities</b>                                                                              | <b>523,276</b>                            |                                     | <b>474,954</b>                                               |                               |                                |



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.  
STATEMENT OF CONSOLIDATED AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

16 Information on Standalone Results :-

| Particulars                                  | Rs. in Lakhs                              |                                     |                                                              |                               |                                |
|----------------------------------------------|-------------------------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|--------------------------------|
|                                              | 3 Months ended 31.03.2017 (Refer note 17) | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 | Previous year ended 31.03.2016 |
|                                              | UNAUDITED                                 | UNAUDITED                           | UNAUDITED                                                    | AUDITED                       | AUDITED                        |
| Total Revenue                                | 58,013                                    | 61,000                              | 72,907                                                       | 228,594                       | 233,051                        |
| Profit before Tax from continuing operations | 9,205                                     | (1,990)                             | 4,736                                                        | 13,813                        | 14,664                         |
| Profit after Tax from continuing operations  | 8,635                                     | (2,434)                             | 5,479                                                        | 12,277                        | 13,193                         |


17 The above results includes the results for the quarter ended March 31, 2017 being the balancing figure between audited figures in respect of the full financial year and the recast published year-to-date figures up to the third quarter of the current financial year.

18 The Board of Directors have proposed a final dividend of Rs. 4.50 per share, which is subject to approval by the shareholders in the Annual General Meeting.

For and on behalf of the Board

Arun Kumar  
Executive Vice Chairman & Managing Director

Bengaluru, May 18, 2017





**INDEPENDENT AUDITORS' REPORT  
TO THE BOARD OF DIRECTORS OF  
STRIDES SHASUN LIMITED (FORMERLY KNOWN AS STRIDES ARCOLAB LIMITED)**

1. We have audited the accompanying Statement of Consolidated Financial Results of **Strides Shasun Limited** (formerly known as **Strides Arcolab Limited**) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the profit of its joint ventures and associates for the year ended March 31, 2017 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and the other financial information of subsidiaries, associates and joint ventures referred to in paragraph 6 below, the Statement:

WJ

(a) includes the results of the following entities:

| Sl. No. | Name of the entities                                                                     |
|---------|------------------------------------------------------------------------------------------|
| 1       | Africa Pharmaceutical Development Company                                                |
| 2       | Akorn Strides LLC                                                                        |
| 3       | Alliance Pharmacy Pty Limited                                                            |
| 4       | Altima Innovation Inc.                                                                   |
| 5       | Aponia Laboratories Inc.                                                                 |
| 6       | Arrow Pharma (Private) Limited (formerly known as Lex Pharma Lanka (Private) Limited)    |
| 7       | Arrow Pharma Life Inc.                                                                   |
| 8       | Arrow Pharma Pte Limited (formerly known as Strides Remedies Pte. Limited)               |
| 9       | Arrow Pharma Pty Limited (formerly known as Strides Arcolab (Australia) Pty Limited)     |
| 10      | Arrow Pharmaceuticals Pty Limited (formerly known as Strides (Australia) IP Pty Limited) |
| 11      | Arrow Remedies Private Limited (formerly known as Lex Pharma Private Limited)            |
| 12      | Beltapharm SpA                                                                           |
| 13      | Chemsynth Laboratories Private Limited                                                   |
| 14      | Congo Pharma SPRL                                                                        |
| 15      | Fagris Medica Private Limited                                                            |
| 16      | Generic Partners (Canada) Inc.                                                           |
| 17      | Generic Partners (International) Pte Limited                                             |
| 18      | Generic Partners (M) Sdn BHd                                                             |
| 19      | Generic Partners (NZ) Limited                                                            |
| 20      | Generic Partners (South Africa) (Pty) Limited                                            |
| 21      | Generic Partners Holding Co Pty Limited                                                  |
| 22      | Generic Partners Pty Limited                                                             |
| 23      | Generic Partners UK Limited                                                              |
| 24      | Oraderm Pharmaceuticals Pty Limited                                                      |
| 25      | Pharmacy Alliance Group Holdings Pty Limited                                             |
| 26      | Pharmacy Alliance Investments Pty Limited                                                |
| 27      | Pharmacy Alliance Pty Limited                                                            |
| 28      | Shasun NBI LLC                                                                           |
| 29      | Shasun Pharma Solutions Inc.                                                             |
| 30      | Shasun Pharma Solutions Limited                                                          |
| 31      | Shasun USA Inc.                                                                          |
| 32      | Smarterpharm Pty Limited                                                                 |
| 33      | Solara Active Pharma Sciences Limited (formerly known as SSL Pharma Sciences Limited)    |
| 34      | Sorepharma SA                                                                            |
| 35      | SPC Co. Limited                                                                          |
| 36      | Stabilis Pharma Inc.                                                                     |

WV

|    |                                                                                        |
|----|----------------------------------------------------------------------------------------|
| 37 | Stelis Biopharma (Malaysia) SDN BDH (formerly known Agila Biotech (Malaysia) SDN BHD)  |
| 38 | Stelis Biopharma Private Limited (formerly known Inbiopro Solutions Private Limited)   |
| 39 | Strides Africa Limited                                                                 |
| 40 | Strides Arcolab (Australia) Pty Limited                                                |
| 41 | Strides Arcolab International Limited                                                  |
| 42 | Strides Biologix Private Limited                                                       |
| 43 | Strides CIS Limited                                                                    |
| 44 | Strides Consumer Private Limited                                                       |
| 45 | Strides Emerging Markets India Private Limited                                         |
| 46 | Strides Healthcare Private Limited (formerly known as Strides Actives Private Limited) |
| 47 | Strides Pharma (Cyprus) Limited                                                        |
| 48 | Strides Pharma (SA)                                                                    |
| 49 | Strides Pharma Asia Pte. Limited (formerly known Agila Specialties Asia Pte. Limited)  |
| 50 | Strides Pharma Botswana (Pty) Limited                                                  |
| 51 | Strides Pharma Cameroon Limited                                                        |
| 52 | Strides Pharma Global (UK) Limited (formerly known as Strides Pharma (UK) Limited)     |
| 53 | Strides Pharma Global Pte Limited                                                      |
| 54 | Strides Pharma Inc.                                                                    |
| 55 | Strides Pharma International Limited                                                   |
| 56 | Strides Pharma Limited                                                                 |
| 57 | Strides Pharma Mozambique                                                              |
| 58 | Strides Pharma Namibia Pty Limited                                                     |
| 59 | Strides Pharma UK Limited (formerly known as Strides Shasun (UK) Limited)              |
| 60 | Strides Shasun Latina Sa de CV                                                         |
| 61 | Strides Specialties (Holdings) Limited                                                 |
| 62 | Strides Vital Nigeria Limited                                                          |
| 63 | SVADS Holdings SA                                                                      |
| 64 | Universal Corporation                                                                  |

- (b) is presented in accordance with the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (c) read with Note 2 of the Statement, gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the Group for the year ended March 31, 2017.

W,

#### **4. Emphasis of Matter**

We draw attention to Note 10 to the Statement regarding the notification of claims received from Mylan under the terms of the Share Purchase Agreements (SPAs) for sale of the investments in entities in the Specialties products business in an earlier year, which the Company had disputed. As further stated in the Note, the Company has provided a guarantee in favour of Mylan and certain amounts have been set aside in the escrows under the terms of the SPAs. During the current year, a significant portion of the claims notified by Mylan has been settled. As explained in the Note, given the nature of the pending claims against the Company and considering the amount held in escrow account, the Company believes that any further outflow of resources is not probable and has made the disclosures under Ind AS 37 "Provisions, Contingent Liabilities and Contingent Assets" in this regard. Our report is not qualified in respect of this matter.

5. In respect of continuing operations, we did not audit the financial statements of 19 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 285,092 Lakhs as at March 31, 2017, total revenues of Rs. 205,450 Lakhs, total net profit after tax of Rs. 16,021 Lakhs and total comprehensive income of Rs. 16,021 Lakhs for the year ended on that date, as considered in the consolidated financial results.

In respect of discontinuing operations, we did not audit the financial statements of 3 subsidiaries included in the consolidated financial results, whose financial statements reflect total revenues of Rs. 4,482 Lakhs, total net profit after tax of Rs. 16,309 Lakhs and total comprehensive income of Rs. 16,309 Lakhs for the year ended on that date, as considered in the consolidated financial results.

These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

6. In respect of continuing operations, the consolidated financial results includes the unaudited financial information of 30 subsidiaries, whose financial information reflect total assets of Rs. 10,815 Lakhs as at March 31, 2017, total revenue of Rs. 6,672 Lakhs, total net profit after tax of Rs. 1,247 Lakhs and total comprehensive income of Rs. 1,247 Lakhs for the year ended on that date, as considered in the consolidated financial results. The consolidated financial results also includes the Group's share of profit after tax of Rs. 36 Lakhs and total comprehensive income of Rs. 36 Lakhs for the year ended March 31, 2017, as considered in the consolidated financial results, in respect of 1 associate and 3 joint ventures, whose financial information have not been audited by us.

In respect of discontinuing operations, the consolidated financial results includes the unaudited financial information of 7 subsidiaries, whose financial information reflect total revenue of Rs. 17,803 Lakhs, total net loss after tax of Rs. 931 Lakhs and total comprehensive loss of Rs. 931 Lakhs for the year ended on that date, as considered in the consolidated financial results.

WJ

These financial information are unaudited and have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial information are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the financial information certified by the Management.

7. The Statement includes the results for the Quarter ended March 31, 2017 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year which is recast to be comparable. The published year to date figures upto the third quarter of the current financial year was subjected to limited review by us.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)




**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

**BENGALURU, May 18, 2017**

STATEMENT OF STANDALONE AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

| Sl. No. | Particulars                                                                       | Rs. in Lakhs                              |                                     |                                                              |                               |                                |
|---------|-----------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|--------------------------------|
|         |                                                                                   | 3 Months ended 31.03.2017 (refer note 14) | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 | Previous year ended 31.03.2016 |
|         |                                                                                   | UNAUDITED (1)                             | UNAUDITED (2)                       | UNAUDITED (3)                                                | AUDITED (4)                   | AUDITED (5)                    |
| I       | Continuing Operations                                                             |                                           |                                     |                                                              |                               |                                |
| II      | Revenue from operations                                                           | 52,280                                    | 57,361                              | 71,758                                                       | 210,980                       | 222,163                        |
| III     | Other Income                                                                      | 5,733                                     | 3,639                               | 1,149                                                        | 17,614                        | 10,888                         |
|         | <b>Total Revenue (I + II)</b>                                                     | <b>58,013</b>                             | <b>61,000</b>                       | <b>72,907</b>                                                | <b>228,594</b>                | <b>233,051</b>                 |
| IV      | Expenses                                                                          |                                           |                                     |                                                              |                               |                                |
|         | (a) Cost of material consumed                                                     | 14,249                                    | 27,028                              | 37,280                                                       | 85,548                        | 118,893                        |
|         | (b) Purchases of stock-in-trade                                                   | 5,917                                     | 1,798                               | 3,831                                                        | 12,388                        | 8,964                          |
|         | (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | 3,340                                     | (1,080)                             | 1,288                                                        | 995                           | 351                            |
|         | (d) Employee benefits expense                                                     | 10,207                                    | 10,226                              | 7,418                                                        | 39,731                        | 27,416                         |
|         | (e) Finance costs                                                                 | 2,922                                     | 2,771                               | 3,444                                                        | 11,474                        | 10,262                         |
|         | (f) Depreciation and amortisation expense                                         | 3,414                                     | 3,314                               | 2,760                                                        | 12,663                        | 10,269                         |
|         | (g) Other expenses                                                                | 10,169                                    | 11,641                              | 11,879                                                       | 44,116                        | 39,552                         |
|         | <b>Total Expenses (IV)</b>                                                        | <b>50,218</b>                             | <b>55,698</b>                       | <b>67,900</b>                                                | <b>206,935</b>                | <b>215,707</b>                 |
| V       | <b>Profit/(loss) before exceptional items and tax (III - IV)</b>                  | <b>7,795</b>                              | <b>5,302</b>                        | <b>5,007</b>                                                 | <b>21,659</b>                 | <b>17,344</b>                  |
| VI      | Exceptional Items:                                                                |                                           |                                     |                                                              |                               |                                |
|         | - Exchange Fluctuation (loss) / gain (Net) (Refer note 13)                        | 2,606                                     | (1,281)                             | 43                                                           | 118                           | (1,635)                        |
|         | - Gain/ (loss) on sale of long term investment                                    | (41)                                      | -                                   | -                                                            | (41)                          | 1,262                          |
|         | - Write-off/provision for impairment of assets (net)                              | (187)                                     | (6,032)                             | -                                                            | (6,488)                       | -                              |
|         | - Interest income                                                                 | -                                         | 124                                 | -                                                            | 124                           | -                              |
|         | - Reversal of provision for impairment of fixed assets                            | -                                         | -                                   | 40                                                           | -                             | 40                             |
|         | - Merger and restructuring costs                                                  | (306)                                     | (103)                               | (192)                                                        | (897)                         | (503)                          |
|         | - Fair valuation of derivative instruments                                        | (662)                                     | -                                   | (162)                                                        | (662)                         | (162)                          |
|         | - Impact of aligning accounting policies on merger of Shasun (Refer note 2)       | -                                         | -                                   | -                                                            | -                             | (1,682)                        |
|         | <b>Total Exceptional Items (VI)</b>                                               | <b>1,410</b>                              | <b>(7,292)</b>                      | <b>(271)</b>                                                 | <b>(7,846)</b>                | <b>(2,680)</b>                 |
| VII     | <b>Profit/(loss) before tax (V + VI)</b>                                          | <b>9,205</b>                              | <b>(1,990)</b>                      | <b>4,736</b>                                                 | <b>13,813</b>                 | <b>14,664</b>                  |
| VIII    | Tax expense                                                                       |                                           |                                     |                                                              |                               |                                |
|         | - Current tax                                                                     | 46                                        | 2,835                               | (1,627)                                                      | 2,781                         | (529)                          |
|         | - Deferred tax                                                                    | 524                                       | (2,391)                             | 884                                                          | (1,245)                       | 2,000                          |
|         | <b>Total tax expense (VIII)</b>                                                   | <b>570</b>                                | <b>444</b>                          | <b>(743)</b>                                                 | <b>1,536</b>                  | <b>1,471</b>                   |
| IX      | <b>Profit/(loss) after tax from continuing operations (VII - VIII)</b>            | <b>8,635</b>                              | <b>(2,434)</b>                      | <b>5,479</b>                                                 | <b>12,277</b>                 | <b>13,193</b>                  |
| X       | Discontinued Operations                                                           |                                           |                                     |                                                              |                               |                                |
|         | - Profit/(loss) from discontinued operations before tax (Refer note 4)            | (1,120)                                   | (17)                                | (158)                                                        | (1,423)                       | (179)                          |
|         | - Tax expense of discontinued operations                                          | -                                         | -                                   | -                                                            | -                             | -                              |
| XI      | <b>Profit/(loss) after tax from discontinued operations</b>                       | <b>(1,120)</b>                            | <b>(17)</b>                         | <b>(158)</b>                                                 | <b>(1,423)</b>                | <b>(179)</b>                   |
| XII     | <b>Profit/(loss) for the period (IX + XI)</b>                                     | <b>7,515</b>                              | <b>(2,451)</b>                      | <b>5,321</b>                                                 | <b>10,854</b>                 | <b>13,020</b>                  |






Regd. Office: No. 201 Devavata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE AUDITED RESULTS

FOR THE YEAR ENDED MARCH 31, 2017

| Sl. No. | Particulars                                                                                  | 3 Months ended 31.03.2017 (refer note 14) |              | Preceding 3 months ended 31.12.2016 |                | Corresponding 3 Months ended 31.03.2016 in the previous year |              | Current year ended 31.03.2017 |               | Previous year ended 31.03.2016 |               |
|---------|----------------------------------------------------------------------------------------------|-------------------------------------------|--------------|-------------------------------------|----------------|--------------------------------------------------------------|--------------|-------------------------------|---------------|--------------------------------|---------------|
|         |                                                                                              | AUDITED                                   | (1)          | UNAUDITED                           | (2)            | AUDITED                                                      | (3)          | AUDITED                       | (4)           | AUDITED                        | (5)           |
| XIII    | Other comprehensive income                                                                   |                                           |              |                                     |                |                                                              |              |                               |               |                                |               |
|         | A (i) Items that will not be recycled to profit or loss                                      |                                           | 122          | -                                   | -              | (50)                                                         | (50)         | (1,440)                       | (1,440)       | (50)                           | (50)          |
|         | (ii) Income tax relating to items that will not be reclassified to profit or loss            |                                           | (43)         | -                                   | -              | 16                                                           | 16           | 498                           | 498           | 16                             | 16            |
|         | B (i) Items that may be recycled to profit or loss                                           |                                           | 2,315        | (754)                               | (754)          | 848                                                          | 848          | 2,002                         | 2,002         | 499                            | 499           |
|         | (ii) Income tax relating to items that may be reclassified to profit or loss                 |                                           | (801)        | 262                                 | 262            | (292)                                                        | (292)        | (693)                         | (693)         | (172)                          | (172)         |
|         | <b>Total other comprehensive income for the period (XIII)</b>                                |                                           | <b>1,593</b> | <b>(492)</b>                        | <b>(492)</b>   | <b>522</b>                                                   | <b>522</b>   | <b>367</b>                    | <b>367</b>    | <b>293</b>                     | <b>293</b>    |
| XIV     | Total comprehensive income for the period (XII + XIII)                                       |                                           | <b>9,108</b> | <b>(2,943)</b>                      | <b>(2,943)</b> | <b>5,843</b>                                                 | <b>5,843</b> | <b>11,221</b>                 | <b>11,221</b> | <b>13,313</b>                  | <b>13,313</b> |
|         | Earnings per share (face value of Rs. 10/- each) (for continuing operation)                  |                                           |              |                                     |                |                                                              |              |                               |               |                                |               |
|         | (a) Basic (Rs.)                                                                              |                                           | 9.66         | (2.72)                              | (2.72)         | 6.14                                                         | 6.14         | 13.74                         | 13.74         | 15.97                          | 15.97         |
|         | (b) Diluted (Rs.)                                                                            |                                           | 9.64         | (2.72)                              | (2.72)         | 6.12                                                         | 6.12         | 13.71                         | 13.71         | 15.88                          | 15.88         |
|         | Earnings per share (face value of Rs. 10/- each) (for discontinuing operation)               |                                           |              |                                     |                |                                                              |              |                               |               |                                |               |
|         | (a) Basic (Rs.)                                                                              |                                           | (1.25)       | (0.02)                              | (0.02)         | (0.18)                                                       | (0.18)       | (1.59)                        | (1.59)        | (0.21)                         | (0.21)        |
|         | (b) Diluted (Rs.)                                                                            |                                           | (1.25)       | (0.02)                              | (0.02)         | (0.18)                                                       | (0.18)       | (1.59)                        | (1.59)        | (0.21)                         | (0.21)        |
|         | Earnings per share (face value of Rs. 10/- each) (for discontinuing & continuing operations) |                                           |              |                                     |                |                                                              |              |                               |               |                                |               |
|         | (a) Basic (Rs.)                                                                              |                                           | 8.41         | (2.74)                              | (2.74)         | 5.96                                                         | 5.96         | 12.15                         | 12.15         | 15.77                          | 15.77         |
|         | (b) Diluted (Rs.)                                                                            |                                           | 8.39         | (2.74)                              | (2.74)         | 5.94                                                         | 5.94         | 12.12                         | 12.12         | 15.67                          | 15.67         |
|         | See accompanying notes to the Financial Results                                              |                                           |              |                                     |                |                                                              |              |                               |               |                                |               |





Regd. Office: No. 201 Devayratta, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE AUDITED RESULTS


FOR THE YEAR ENDED MARCH 31, 2017

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2017

|                                           |  | Rs in Lakhs      |                  |                  |
|-------------------------------------------|--|------------------|------------------|------------------|
| Particulars                               |  | As at 31.03.2017 | As at 31.03.2016 | As at 01.04.2015 |
|                                           |  | AUDITED          | AUDITED          | AUDITED          |
| <b>A ASSETS</b>                           |  |                  |                  |                  |
| <b>I Non-current assets</b>               |  |                  |                  |                  |
| (a) Property, Plant and Equipment         |  | 84,152           | 70,447           | 25,268           |
| (b) Capital Work in Progress              |  | 9,962            | 12,642           | 2,107            |
| (c) Investment Property                   |  | 7,007            | 7,403            | 7,764            |
| (d) Goodwill                              |  | 7,499            | 7,499            | -                |
| (e) Other intangible assets               |  | 20,727           | 20,412           | 6,420            |
| (f) Intangibles assets under development  |  | 5,811            | 5,366            | 1,802            |
| (g) Financial assets                      |  |                  |                  |                  |
| (i) Investments                           |  | 131,918          | 123,392          | 40,717           |
| (ii) Loans                                |  | 3,659            | 2,576            | 427              |
| (iii) Other financial assets              |  | 1,972            | 2,046            | 588              |
| (h) Deferred tax assets (Net)             |  | -                | -                | -                |
| (i) Other Non-current assets              |  | 18,728           | 17,683           | 8,436            |
|                                           |  | <b>291,435</b>   | <b>269,468</b>   | <b>93,529</b>    |
| <b>II Current assets</b>                  |  |                  |                  |                  |
| (a) Inventories                           |  | 40,953           | 37,923           | 15,540           |
| (b) Financial assets                      |  |                  |                  |                  |
| (i) Investments - Current                 |  | 127,954          | 113,910          | 59,952           |
| (ii) Trade receivables                    |  | 53,437           | 69,239           | 25,401           |
| (iii) Cash and cash equivalents           |  | 8,777            | 8,732            | 6,603            |
| (iv) Bank balances other than (iii) above |  | 715              | 702              | 827              |
| (v) Loans                                 |  | 1,072            | 4,759            | 4,252            |
| (vi) Other financial assets               |  | 5,342            | 11,953           | 6,541            |
| (c) Current tax assets (Net)              |  | 1,475            | 416              | -                |
| (d) Other current assets                  |  | 19,564           | 17,087           | 6,045            |
|                                           |  | <b>259,289</b>   | <b>264,721</b>   | <b>125,361</b>   |
|                                           |  | <b>550,724</b>   | <b>534,189</b>   | <b>218,890</b>   |
| <b>B EQUITY AND LIABILITIES</b>           |  |                  |                  |                  |
| <b>I Equity</b>                           |  |                  |                  |                  |
| (a) Equity Share capital                  |  | 8,942            | 8,935            | 5,962            |
| (b) Other equity                          |  | 314,311          | 306,827          | 144,131          |
| <b>Total Equity</b>                       |  | <b>323,253</b>   | <b>315,762</b>   | <b>150,093</b>   |
| <b>II Liabilities</b>                     |  |                  |                  |                  |
| <b>1 Non-current liabilities</b>          |  |                  |                  |                  |
| (a) Financial Liabilities                 |  |                  |                  |                  |
| (i) Borrowings                            |  | 77,115           | 86,761           | 16,425           |
| (ii) Other financial liabilities          |  | 2,130            | 1,924            | 1,680            |
| (iii) Provisions                          |  | 1,792            | 1,014            | 548              |
| (c) Deferred tax liabilities (Net)        |  | 2,753            | 3,802            | 1,459            |
| (d) Other non-current liabilities         |  | 2,581            | 1,058            | 905              |
|                                           |  | <b>86,171</b>    | <b>94,559</b>    | <b>21,017</b>    |
| <b>2 Current liabilities</b>              |  |                  |                  |                  |
| (a) Financial Liabilities                 |  |                  |                  |                  |
| (i) Borrowings                            |  | 64,744           | 54,338           | 16,266           |
| (ii) Trade payables                       |  | 47,070           | 49,718           | 18,863           |
| (iii) Other financial liabilities         |  | 23,877           | 16,702           | 9,397            |
| (b) Other current liabilities             |  | 4,117            | 2,245            | 942              |
| (c) Provisions                            |  | 1,492            | 865              | 1,282            |
| (d) Current tax liabilities               |  | -                | -                | 1,030            |
|                                           |  | <b>141,300</b>   | <b>123,868</b>   | <b>47,780</b>    |
|                                           |  | <b>550,724</b>   | <b>534,189</b>   | <b>218,890</b>   |
| <b>Total Equity and liabilities</b>       |  |                  |                  |                  |
|                                           |  | <b>550,724</b>   | <b>534,189</b>   | <b>218,890</b>   |







Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Stides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 18 May 2017.
- 2 During the previous year, pursuant to the court approved Scheme of Amalgamation (the 'Scheme'), the erstwhile Shasun Pharmaceuticals Limited (Shasun) has been amalgamated with the Company w.e.f. the appointed date of April 01, 2015.

Ind AS 103 'Business Combination' is not applicable to the above referred merger in view of the Scheme sanctioned by the Hon'ble High Courts of Judicature under section 391 to 394 of the Companies Act, 1956.

The Company has followed the 'Pooling of Interest method' as per the court approved Scheme of Amalgamation for the accounting of Assets and Liabilities of the erstwhile Shasun. The impact of aligning the accounting policies of the erstwhile Shasun with that of the Company on the assets and liabilities taken over on merger amounting to Rs. 1,682 lakhs has been expensed off in the results for the year ended 31 March 2016 under exceptional items.


The Company issued 21,017,329 equity shares of Rs. 10/- each to the shareholders of erstwhile Shasun in terms of the Scheme of Amalgamation. These shares have been considered for the purpose of calculation of earnings per share


**3 Transition to Indian Accounting Standards (Ind AS):**

The Standalone financial statements for the year ended March 31, 2017 are prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015. The adoption of Ind AS was carried out in accordance with Ind AS 101, using April 01, 2015 as the transition date. Ind AS 101 requires that all the Ind AS standards and interpretations that are effective for the Ind AS financial statements for the year ended March 31, 2017 be applied consistently and retrospectively for all fiscal years presented. All applicable Ind AS, read with note 2 above, have been applied consistently and retrospectively wherever required. The resulting difference in the carrying amounts of assets and liabilities in the financial statements under both Ind AS and Indian GAAP as at the transition date have been recognised directly in equity at the transition date.

The following reconciliations provide a quantification of the effect of significant differences arising from the transition from India GAAP to Ind AS in accordance with Ind AS 101:

- (a) Equity as at April 01, 2015  
(b) Equity as at March 31, 2016  
(c) Total comprehensive income for the year ended March 31, 2016





Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.


STATEMENT OF STANDALONE AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017


Equity reconciliation

| Particulars                                                               | Rs. In Lakhs   |                |
|---------------------------------------------------------------------------|----------------|----------------|
|                                                                           | March 31, 2016 | Apr 01, 2015   |
| Equity under previous GAAP as reported                                    | 304,606        | 141,481        |
| Reversal of proposed dividend and taxes                                   | 4,321          | 1,787          |
| Measurement of Actuarial gains/ losses through OCI                        | (33)           | -              |
| Impact of measuring ESOP at fair value                                    | (331)          | -              |
| Fair value of investment                                                  | (708)          | 2,500          |
| Impairment under ECL                                                      | (990)          | -              |
| Reversal of amortisation on account of change in estimated useful life of | 248            | (1,334)        |
| Recognition of Put option liability                                       | (1,496)        | 9              |
| Other adjustments                                                         | 499            | (312)          |
| Unrealised gain/ (loss) on hedge through OCI                              | 711            | -              |
| Tax Impact of the above                                                   | -              | -              |
| <b>Balance as per IND AS</b>                                              | <b>306,827</b> | <b>144,131</b> |

Total comprehensive income reconciliation

| Particulars                                                                                 | Rs. In Lakhs                 |                            |                              |                            |
|---------------------------------------------------------------------------------------------|------------------------------|----------------------------|------------------------------|----------------------------|
|                                                                                             | Quarter ended March 31, 2016 |                            | Year ended March 31, 2016    |                            |
|                                                                                             | Statement of Profit and loss | Other comprehensive Income | Statement of Profit and loss | Other comprehensive Income |
| Profit under previous GAAP as reported                                                      | 5,964                        | -                          | 16,107                       | -                          |
| Loss on fairvaluation of current investment                                                 | 164                          | -                          | (3,208)                      | -                          |
| Impact of measuring ESOP at fair value                                                      | (90)                         | -                          | (331)                        | -                          |
| Impairment under ECL                                                                        | (990)                        | -                          | (990)                        | -                          |
| Impact on account of discounting of deposits                                                | 2                            | -                          | 3                            | -                          |
| Write off of stamp duty on registration of Intangible assets acquired                       | (48)                         | -                          | (48)                         | -                          |
| Reversal of amortisation on account of change in estimated useful life of Intangible assets | 248                          | -                          | 248                          | -                          |
| Fair valuation of option contracts                                                          | (162)                        | -                          | (162)                        | -                          |
| Actuarial gains/ losses through OCI                                                         | 50                           | (50)                       | 50                           | (50)                       |
| Unrealised gain/ (loss) on hedge through OCI                                                | -                            | 848                        | -                            | 499                        |
| Tax Impact of the above                                                                     | 183                          | (276)                      | 1,351                        | (156)                      |
| <b>Balance as per IND AS</b>                                                                | <b>5,321</b>                 | <b>522</b>                 | <b>13,020</b>                | <b>293</b>                 |
|                                                                                             |                              |                            |                              | <b>13,313</b>              |





Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017

4. Sale of Investments:


(a) During the current quarter, the Company sold its investments in Strides Biologix Private Limited, India (Strides Biologix) an erstwhile subsidiary, and the related business. The gain on sale of Strides Biologix amounting to INR 308 Lakhs is included in discontinued operations and the results of this business are included in the details of the discontinued operations for the respective periods as set out in Note 4(c) below.


(b) Pursuant to the terms of Shareholders agreement entered on March 30, 2017, the Group disposed-off its Pharma Generics Manufacturing business in Africa. Consequently, the following subsidiaries / divisions ceased to be part of Strides Group:

- (i) African Pharmaceutical Development Company
- (ii) Congo Pharma SPRL
- (iii) Sorepharm SA
- (iv) Strides Pharma Botswana (Pty) Limited
- (v) Strides Pharma Cameroon Limited
- (vi) Strides Pharma Mozambique, SA
- (vii) Strides Pharma Namibia Pty Limited
- (viii) Strides Vital Nigeria Limited
- (ix) SPC Co. Limited, Sudan
- (x) Pharma Generics Manufacturing division of the Company in Palghar, Maharashtra.

The loss on disposal of the Pharma Generics Manufacturing division in Palghar, Maharashtra amounting Rs.1,419 Lakhs the results of this business for the period are included in the discontinued operations as set out in Note 4(c) below:

| c) Discontinued Operations |                                                              | Rs. In Lakhs              |                                     |                                                              |                               |                                |
|----------------------------|--------------------------------------------------------------|---------------------------|-------------------------------------|--------------------------------------------------------------|-------------------------------|--------------------------------|
|                            |                                                              | 3 Months ended 31.03.2017 | Preceding 3 months ended 31.12.2016 | Corresponding 3 Months ended 31.03.2016 in the previous year | Current year ended 31.03.2017 | Previous year ended 31.03.2016 |
| Sl. No.                    | Particulars                                                  | UNAUDITED (1)             | UNAUDITED (2)                       | UNAUDITED (3)                                                | AUDITED (4)                   | AUDITED (5)                    |
| I                          | Total Revenue                                                | 878                       | 687                                 | 1,065                                                        | 3,284                         | 4,006                          |
| II                         | Total Expenses                                               | 887                       | 704                                 | 1,223                                                        | 3,596                         | 4,179                          |
| III                        | Profit/(loss) before exceptional items and tax (I - II)      | (9)                       | (17)                                | (158)                                                        | (312)                         | (173)                          |
| IV                         | Exceptional items:                                           | -                         | -                                   | -                                                            | -                             | -                              |
| V                          | Profit/(loss) before tax (III + IV)                          | (9)                       | (17)                                | (158)                                                        | (312)                         | (173)                          |
| VI                         | Tax expense                                                  | -                         | -                                   | -                                                            | -                             | -                              |
| VII                        | Profit/(loss) after tax (V-VI)                               | (9)                       | (17)                                | (158)                                                        | (312)                         | (173)                          |
| VIII                       | Gain/ (loss) on disposals as mentioned in 4(a) and (b) above | (1,111)                   | -                                   | -                                                            | (1,111)                       | -                              |
| IX                         | Gain/ (loss) from discontinued operations (VII+VIII)         | (1,120)                   | (17)                                | (158)                                                        | (1,423)                       | (173)                          |





Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.  
Corp. Office: 'Strides House', Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE AUDITED RESULTS  
FOR THE YEAR ENDED MARCH 31, 2017**

5 As part of ongoing restructuring in the group, the following changes have been made during the quarter ended 31 March 2017, within the Strides group:

- (a) Strides Specialities (Holdings) Limited, Mauritius, transferred from Strides Pharma Global Pte Limited, Singapore, to Strides Pharma Asia Pte Limited, Singapore.
- (b) Stelis Biopharma (Malaysia) SDN BHD, Malaysia, transferred from Stelis Biopharma Private Limited, India to Strides Pharma Asia Pte Limited, Singapore.
- (c) Strides Pharma Solutions Inc., USA, and Stelis Pharma Inc., USA, transferred from SVADS Holdings SA, Switzerland to Strides Arcolab International Limited, UK.

6 Pursuant to the approvals of the board of directors of the Company and that of the shareholders received vide a postal ballot dated March 22, 2017, with regard to the Company's intent of capping its investments in Stelis Biopharma Private Limited ("Stelis", a company which is into development of Biosimilars") and its intention of reducing its stake to a significant minority, the Company entered into an amended shareholders agreement under which it has ceded control over Stelis but continues to exercise significant influence.

- 7 In the current quarter, pursuant to the Group acquiring remaining stake in Fagris Medica Private Limited, India and Arrow Pharma Pte Limited, Singapore, these entities became wholly owned subsidiaries of the Group
- 8 During the quarter ended 31 March 2017, Solara Active Pharma Sciences Limited (formerly known as SSL Pharma Sciences Limited) and Strides Consumer Private Limited, India, were incorporated as wholly owned subsidiaries of the Group.

9 On December 4, 2013, the Company and its wholly owned subsidiary, Strides Pharma Asia Pte Limited ("the Singapore Subsidiary"), completed the sale of investments in Agila Specialities Private Limited and Agila Specialities Global Pte Limited (together, "Agila") to Mylan Laboratories Limited and Mylan Institutional Inc. (together, "Mylan") pursuant to separate agreements, each dated as of February 27, 2013 (the "SPAs"). Pursuant to the SPAs, the Strides Group established escrow arrangements to fund certain potential indemnification liabilities, including specified employee, tax and regulatory remediation costs from such consideration. These escrow arrangements included a US\$ 100 million 'General Claims Escrow' deposit (out of which US\$ 8.00 million has been settled in an earlier year to be paid to Mylan in relation to certain claims) and a US\$ 100 million 'Regulatory Escrow' deposit. Pursuant to the SPAs, the Company has also provided a corporate guarantee to Mylan for US\$ 200 million (valid up to December 4, 2020) on behalf of Singapore Subsidiary which can be used for discharging financial obligations, if any, of the Singapore Subsidiary to Mylan.

Under the terms of the SPAs, claims against the Company / the Singapore subsidiary (as the case may be) can only be made under specific provisions contained in the SPAs which include the procedures and timelines for submission of notifications of claims and actual claims and commencing arbitration proceedings. The Company had received a consolidated notification of claims from Mylan under the terms of the SPAs.

These claims were related to third party claims, tax claims, claims against the regulatory escrows and general claims. In the current year, a significant portion of these claims have been settled and the Strides Group has received approximately USD 28 Million as full and final settlement from out of the Regulatory Escrow deposit. Further, the Company and Mylan also agreed on full and final settlement of warranty and indemnity claims to be adjusted against the 'General Claims Escrow'.

Considering the terms of the SPAs, the nature of the pending claims that are in arbitration currently and the balance available in the General Claims Escrow deposit, the Company believes that any further outflow of resources is not probable.

10 The Company has entered into definitive agreement with Perrigo Group for acquisition of Perrigo API India Private Limited. As at 31 March 2017, pending completion of certain conditions precedent and other customary closing condition, this acquisition has not been completed. On April 6, 2017 the company has completed the acquisition of Perrigo API India Private Limited.

11 Income from Operations includes revenues from sale of products, product development services, royalties, export entitlements etc. Cost of material consumed is net of rebates, discounts, supplier reimbursements.

12 During the year ended 31 March 2017, 70,000 equity shares and 7,028 equity shares were allotted by the Company under the Strides Arcolab ESOP 2011 Scheme and Strides Arcolab ESOP 2015 Scheme, respectively, on exercising equal number of options.


13 Exchange fluctuation gain/loss (net) included under Exceptional Items comprises the exchange gain / loss arising on account of restatement and settlement of long term foreign currency loans and intra-group loans

14 The above results includes the results for the quarter ended March 31, 2017 being the balancing figure between audited figures in respect of the full financial year and the restated published year-to-date figures up to the third quarter of the current financial year.

15 The Board of Directors have proposed a final dividend of Rs 4.50 per share, which is subject to the approval by the shareholders in the Annual General Meeting

For and on behalf of the Board

Arun Kumar  
Executive Vice Chairman & Managing Director



**INDEPENDENT AUDITOR'S REPORT  
TO THE BOARD OF DIRECTORS OF  
STRIDES SHASUN LIMITED (FORMERLY KNOWN AS STRIDES ARCOLAB LIMITED)**

1. We have audited the accompanying Statement of Standalone Financial Results of **Strides Shasun Limited (formerly known as Strides Arcolab Limited)** ("the Company"), for the year ended 31 March 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us the Statement:
  - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - (ii) read with Note 2 of the Statement, gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year ended 31 March 2017.

aw,

**4. Emphasis of Matter**

We draw attention to Note 9 to the Statement regarding the notification of claims received from Mylan under the terms of the Share Purchase Agreements (SPAs) for sale of the investments in entities in the Specialties products business in an earlier year, which the Company had disputed. As further stated in the Note, the Company has provided a guarantee in favour of Mylan and certain amounts have been set aside in escrows under the terms of the SPAs. During the current year, a significant portion of the claims notified by Mylan has been settled. As explained in the Note, given the nature of the pending claims against the Company and considering the amount held in the escrow account, the Company believes that any further outflow of resources is not probable and has made the disclosures under Ind AS 37 "Provisions, Contingent Liabilities and Contingent Assets" in this regard. Our report is not qualified in respect of this matter.

5. The Statement includes the results for the Quarter ended March 31, 2017 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year which is recast to be comparable. The published year to date figures upto the third quarter of the current financial year was subjected to limited review by us.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Sathya P. Koushik**  
Partner  
(Membership No. 206920)

**BENGALURU, May 18, 2017**